Terms: = Endocrine gland cancer AND MUC16, CA125, CA-125
5170 results:
1. Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
Cheng Y; Li Q; Sun G; Li T; Zou Y; Ye H; Wang K; Shi J; Wang P
Sci Rep; 2024 Apr; 14(1):9757. PubMed ID: 38684875
[TBL] [Abstract] [Full Text] [Related]
2. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
Guo J; Zeng X; Zhu Y; Yang D; Zhao X
J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
[TBL] [Abstract] [Full Text] [Related]
3. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
4. Efficient CAR T cell targeting of the ca125 extracellular repeat domain of muc16.
Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
[TBL] [Abstract] [Full Text] [Related]
5. Bayesian and deep-learning models applied to the early detection of ovarian cancer using multiple longitudinal biomarkers.
Abrego L; Zaikin A; Marino IP; Krivonosov MI; Jacobs I; Menon U; Gentry-Maharaj A; Blyuss O
Cancer Med; 2024 Apr; 13(7):e7163. PubMed ID: 38597129
[TBL] [Abstract] [Full Text] [Related]
6. Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in ca125 and CA15-3.
Ekman M; Salminen T; Raiko K; Soukka T; Gidwani K; Martiskainen I
Anal Bioanal Chem; 2024 May; 416(13):3251-3260. PubMed ID: 38584178
[TBL] [Abstract] [Full Text] [Related]
7. Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.
Al-Alem L; Prendergast JM; Clark J; Zarrella B; Zarrella DT; Hill SJ; Growdon WB; Pooladanda V; Spriggs DR; Cramer D; Elias KM; Nazer RI; Skates SJ; Behrens J; Dransfield DT; Rueda BR
J Ovarian Res; 2024 Apr; 17(1):71. PubMed ID: 38566237
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of the Cutoff Point and Diagnostic Value of the Neutrophil-to-Lymphocyte Ratio in Predicting Ovarian cancer Compared to Pathological Findings.
Hosseini MS; Amiri F; Rezapour M; Ashraf Ganjoie T; Farzaneh F; Arab M; Talayeh M; Beheshti Rooy R; Hadi F
Asian Pac J Cancer Prev; 2024 Mar; 25(3):971-976. PubMed ID: 38546079
[TBL] [Abstract] [Full Text] [Related]
9. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
[No Abstract] [Full Text] [Related]
10. Interrogating the Theranostic Capacity of a muc16-Targeted Antibody for Ovarian cancer.
Mack KN; Samuels ZV; Carter LM; Viray TD; Mandleywala K; Brooks CL; Hollingsworth MA; Radhakrishnan P; Lewis JS
J Nucl Med; 2024 Apr; 65(4):580-585. PubMed ID: 38485271
[TBL] [Abstract] [Full Text] [Related]
11. Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic cancer: A Multicenter Cohort Study.
Huang J; Gao G; Ge Y; Liu J; Cui H; Zheng R; Wang J; Wang S; Go VL; Hu S; Liu Y; Yang M; Sun Y; Shang D; Tian Y; Zhang Z; Xiang Z; Wang H; Guo J; Xiao GG
Dig Dis Sci; 2024 Apr; 69(4):1263-1273. PubMed ID: 38451429
[TBL] [Abstract] [Full Text] [Related]
12. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G; Floquet A; Tredan O; Carrot A; Langlois-Jacques C; Lopez J; Selle F; Abdeddaim C; Leary A; Dubot-Poitelon C; Fabbro M; Gladieff L; Lamuraglia M
Nat Commun; 2024 Mar; 15(1):1985. PubMed ID: 38443333
[TBL] [Abstract] [Full Text] [Related]
13. Development of an Automatic Rule-Based Algorithm for the Detection of Ovarian cancer Recurrence From Electronic Health Records.
Lee S; Kim JH; Ha HI; Lim MC; Cho H
JCO Clin Cancer Inform; 2024 Mar; 8():e2300150. PubMed ID: 38442323
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic value of plasma-derived exosomal miR-223 for epithelial ovarian cancer.
Yang L; Yang Z; Liu Z; Qi N; Tao L
BMC Womens Health; 2024 Mar; 24(1):150. PubMed ID: 38431592
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer.
Wu M; Gu S; Yang J; Zhao Y; Sheng J; Cheng S; Xu S; Wu Y; Ma M; Luo X; Zhang H; Wang Y; Zhao A
BMC Cancer; 2024 Feb; 24(1):267. PubMed ID: 38408960
[TBL] [Abstract] [Full Text] [Related]
16. Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer.
Jia Y; Jiang Y; Fan X; Zhang Y; Li K; Wang H; Ning X; Yang X
World J Surg Oncol; 2024 Feb; 22(1):64. PubMed ID: 38395933
[TBL] [Abstract] [Full Text] [Related]
17. An integrated machine learning-based model for joint diagnosis of ovarian cancer with multiple test indicators.
Feng Y
J Ovarian Res; 2024 Feb; 17(1):45. PubMed ID: 38378582
[TBL] [Abstract] [Full Text] [Related]
18. Structural basis for antibody recognition of the proximal muc16 ectodomain.
Lee K; Perry K; Xu M; Veillard I; Kumar R; Rao TD; Rueda BR; Spriggs DR; Yeku OO
J Ovarian Res; 2024 Feb; 17(1):41. PubMed ID: 38374055
[TBL] [Abstract] [Full Text] [Related]
19. A computer synoptic operative report versus a report dictated by a surgeon in advanced ovarian cancer.
Bedel A; Blache G; Jauffret C; Houvenaeghel G; Buttarelli M; Sabiani L; Mokarram Dorri N; El Hajj H; Lambaudie E
Int J Gynecol Cancer; 2024 Apr; 34(4):581-585. PubMed ID: 38336374
[TBL] [Abstract] [Full Text] [Related]
20. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
[Next]
